Gilead Statement of Disclosure and Compliance with Section 54 of the Modern Slavery Act (UK) andthe California Transparency in Supply Chains ActIntroduction
Gilead Sciences Ltd, Gilead Sciences International Ltd. and Gilead Sciences Europe Ltd. (collectively,"Gilead UK") and Gilead Sciences, Inc. and Kite Pharma, Inc. (collectively, "Gilead US"; together with
Gilead UK, "Gilead"), are committed to maintaining the highest standards of legal and ethical conduct.
Gilead recognises the seriousness and importance of combatting modern slavery and human trafficking
and is committed to fully understanding and taking all appropriate action to address any slavery andhuman trafficking risks in our own business and in our supply chains.
Our Business
Gilead is committed to creating a healthier world for all people, and has a mission to discover, develop
and deliver innovative therapeutics for people with life-threatening diseases through bold andtransformative sciences. Gilead's principal business activity is the development, manufacture, sale anddistribution of pharmaceutical products for human healthcare. Gilead operates in a highly regulatedenvironment. It uses a combination of Gilead owned facilities and strategic third-party partners to
manufacture and distribute Gilead products worldwide. Gilead sells pharmaceutical products to hospitals,
retail pharmacies and other healthcare providers in the UK, US and worldwide. Gilead also provides
technical and support services to group companies in connection with our pharmaceutical products.
Gilead's global headquarters are located in Foster City, California. Gilead UK is based in the UK and carriesout business in the UK. Gilead US is based in the US and carries out business in the US and worldwide.
Gilead operates and manages its subsidiaries through global policies, systems and processes that aredesigned to ensure consistency across the group, including third party contract governance, audit
processes and oversight. In September 2022, Gilead acquired MiroBio Ltd (a UK company, but not areporting entity for the purposes of this statement) and has made considerable progress integrating
MiroBio into Gilead’s operational practices. Gilead continues to work to ensure that MiroBio complies
with the same standards as Gilead UK in order to mitigate the risks of modern slavery within MiroBio.
Gilead’s Employees
Gilead believes that the risk of modern slavery in our directly employed workforce is relatively low. Thisis due in part to the highly regulated nature of the pharmaceutical industry, and to our employees being
largely educated or skilled, and/or undertaking work in controlled environments such as Gilead offices
and laboratories. Nevertheless, we recognise that there is a risk that needs to be addressed. One way
we have addressed this risk is by reorganising the way we carry out the recruitment of our directly
employed workforce. We have consolidated our recruitment supply base so that we now work closelywith only a few strategic partners on a global basis, rather than with a large number of third-party
recruitment agencies.
Code of Ethics
Gilead's Core Values are integrity, teamwork, accountability, inclusion and excellence, embedding respectfor human rights and labour rights across the business. This includes demonstrating ethical and moral
conduct, as well as adhering to laws, regulations, and company policies. The Core Values, in particular thevalues of integrity and accountability, are interwoven throughout Gilead's Code of Ethics, which all ourpersonnel (our officers, directors, employees, temporary staff and contractors, hereafter collectively"Personnel") are required to comply with. Gilead also expects and requires all third parties performing
services for us, or with whom we partner or collaborate, to act in a way which is consistent with theprinciples in our Code of Ethics. Human rights and sustainability are part of our Code of Ethics.
Reporting, Investigating Concerns and Internal Accountability
Gilead Personnel are required to report potential violations of laws, regulations, company policies(including the Gilead Code of Ethics) and any other serious wrongdoing within Gilead. To facilitate
disclosures and help protect anonymity, Personnel can report any concerns through Gilead's Ethics
Hotline. Gilead investigates all allegations of misconduct and circumstances that implicate potential
violations of laws, regulations or company policies. Violations are not tolerated and can lead to
disciplinary action, including termination of employment (where applicable).
Supplier Code of Conduct
Gilead recognises that exposure to the risk of modern slavery increases when we engage with thirdparties, particularly in such areas of our business as catering, cleaning, transportation, protective
equipment and clothing, warehousing, construction, manufacturing, packaging, and promotional goods
suppliers.
As part of our procurement and supply chain strategy, we employ responsible sourcing, supplier inclusion,
auditing procedures, green chemistry and sustainable manufacturing and distribution principles tominimize the impact from our procurement and supply chain practices.
Just as Gilead does not condone the use of slavery or human trafficking in our own operations, we do nottolerate such practices within our supply chain, and we endeavour to select suppliers who share thesestandards. Gilead maintains a Code of Conduct for suppliers (“Supplier Code of Conduct”), reflecting theimportance to Gilead of ethical business practices and principles of behaviour. The Supplier Code ofConduct stipulates that suppliers must comply with applicable laws, regulations and Gilead standards, andprohibits the use of forced labour or human trafficking within the supply chain. In 2023, Gilead initiatedrevisions to the Supplier Code of Conduct with a view to further strengthening the Code’s commitment tohuman rights.
Supplier Certification
Gilead expects its suppliers to apply the principles of the Supplier Code of Conduct during the performanceof each supplier’s responsibilities. As Gilead’s business expands into new markets and supply chains,
Gilead has translated its Supplier Code of Conduct into ten languages. The Supplier Code of Conduct cantherefore be shared with prospective suppliers globally and used as part of the supplier selection process.
Refusal by a supplier to commit to the Supplier Code of Conduct’s principles is an important factor in
deciding whether to do business with a supplier.
All contractual arrangements between Gilead and our suppliers stipulate compliance with applicable laws
and regulations, and in some cases specifically reference laws concerning slavery and human trafficking.
Gilead is entitled to terminate supplier contracts where suppliers have not met their contractual
obligations in this regard. Gilead encourages suppliers to use management systems to facilitate continualimprovement and compliance with the expectations of the Supplier Code of Conduct, and to identify,
assess and manage risks in all areas, including their own operations and supply chains.
Supplier Audits
Gilead monitors its suppliers as part of our supplier relationship management programme. This may
involve routine in-person meetings between Gilead management and our suppliers where appropriate.
Gilead uses its own Personnel and, also in certain circumstances, independent third parties, to carry out
regular and ad hoc audits and site inspections of our manufacturing and packaging suppliers to ensurecompliance with quality agreements. These suppliers may also be subject to ad hoc audits and inspection
by government authorities.
Whilst slavery and human trafficking are not specific targets of these audits, Gilead Personnel conducting
these audits are expected to escalate any such observations or suspicions immediately. In 2023, there
were no issues raised that were associated with forced or child labour in the facilities audited under thisprogramme.
Gilead’s supplier assessment programme aids Gilead in addressing social and ethical risks (including healthand safety; human trafficking; modern slavery, including forced, bonded, involuntary prison and childlabour; discrimination and unfair treatment; and business integrity), environmental, operational, andother risks within its supply chain.
Gilead must be satisfied that suppliers protect workers as evidenced through health and safety
performance and by other means, including verification of the management framework for accident or
injury, investigation and checks on incident records during onsite assessments of suppliers, and satisfying
ourselves that worker protection is under the direction of clearly identified and accountable individuals
possessing the appropriate technical and managerial skills, training, and knowledge.
In 2023, Gilead completed supplier site assessment audits that directly utilised the Pharmaceutical Supply
Chain Initiative (“PSCI”) resources and approaches. These PSCI audits generally consider all or part of thepillars described in the PSCI Principles (i.e. Ethics, Labor & Human Rights, Health & Safety, Environmentand Management Systems) and in the PSCI Audit Guidance. We continue to evaluate the most practicableand effective ways to ensure compliance and continual improvement amongst our value chain partners.
Training
As part of responsible sourcing management programmes, Gilead provides targeted on-line and inperson training to key Personnel involved in the management of suppliers which specifically addresses
slavery and human trafficking. Gilead intends to provide training on these legal risks at a broader level toother business functions within the organisation once we have completed our current enterprise-widereassessment of third-party risk management.
UK Supply Chain Controls
Gilead UK requires key suppliers to comply with the Modern Slavery Act 2015 ("Act") and the Supplier
Code of Conduct. Furthermore, Gilead UK’s standard supply of services contract requires all suppliers towarrant that they are not aware of any conduct or circumstances within any part of their business or
supply chain anywhere in the world that may constitute slavery and human trafficking, as defined insection 54(12) of the Act. In its higher risk contracts, Gilead UK has the right to audit suppliers to ensure
they comply with the Act.
Industry Collaboration
Gilead invests in cross-industry collaboration as part of our ongoing efforts to address a wide range ofglobal challenges that affect communities worldwide. Gilead has chosen to join other like-minded
companies in support of the United Nations Global Compact (“UNGC”) - a voluntary initiative that isdesigned to align industries in the name of human rights, labour standards, environmental protection,
and anti-corruption practices. Gilead is integrating the UNGC principles into our strategy, culture, and dayto-day operations.
Additionally, Gilead is committed to responsible supply chain practices. Gilead joined the PSCI in 2018.
The PSCI has developed a framework that can be leveraged to address common issues in pharmaceuticalsupply chains: (1) Freely Chosen Employment, (2) Child Labor and Young Workers, (3) Non-Discrimination,(4) Fair Treatment, (5) Wages, Benefits, and Working Hours, and (6) Freedom of Association. Thesestandards set our expectations on these issues. As a member of PSCI, Gilead promotes responsible
practices that will continuously improve social, health, safety, and environmentally sustainable outcomes.
Gilead actively participates in PSCI committees, driving positive change within Gilead, and across thepharmaceutical industry through collaborative efforts with peer member companies. Gilead’s
involvement with PSCI continues to shape our implementation of best practices, as evidenced above byutilisation of PSCI standards and approaches in the audit activities we conduct in our key supplier facilities.
California Transparency in Supply Chains Act
This statement is made pursuant to the California Transparency in Supply Chains Act of 2010 (SB 657) inrespect of Gilead US.
UK Modern Slavery Act
This statement is made pursuant to section 54(1) of the Act in respect of Gilead UK and constitutes theslavery and human trafficking statement for the financial year ending 31 December 2023 for Gilead UKand sets out the steps taken to address modern slavery risks in our business and supply chains. It has
been approved by the board of directors of each Gilead UK company and signed by a director of eachcompany.

...........................................

June 25, 2024 | 10:27:41 AM PDT

Date: ……………………………….

John Jorden, Vice President FinanceDirector:
Gilead Sciences Ltd

Gilead Sciences International Ltd
Gilead Sciences Europe Ltd